Placebo-controlled study of rTMS for the treatment of Parkinson's disease.
Identifieur interne : 002E37 ( PubMed/Corpus ); précédent : 002E36; suivant : 002E38Placebo-controlled study of rTMS for the treatment of Parkinson's disease.
Auteurs : Mikhail P. Lomarev ; Sulada Kanchana ; William Bara-Jimenez ; Meena Iyer ; Eric M. Wassermann ; Mark HallettSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2006.
English descriptors
- KwdEn :
- Evoked Potentials, Motor (physiology), Female, Hand (physiopathology), Humans, Hypokinesia (physiopathology), Hypokinesia (therapy), Male, Middle Aged, Motor Cortex (physiopathology), Parkinson Disease (diagnosis), Parkinson Disease (physiopathology), Parkinson Disease (therapy), Prefrontal Cortex (physiopathology), Severity of Illness Index, Transcranial Magnetic Stimulation (instrumentation), Walking.
- MESH :
- diagnosis : Parkinson Disease.
- instrumentation : Transcranial Magnetic Stimulation.
- physiology : Evoked Potentials, Motor.
- physiopathology : Hand, Hypokinesia, Motor Cortex, Parkinson Disease, Prefrontal Cortex.
- therapy : Hypokinesia, Parkinson Disease.
- Female, Humans, Male, Middle Aged, Severity of Illness Index, Walking.
Abstract
The objective of this study is to assess the safety and efficacy of repetitive transcranial magnetic stimulation (rTMS) for gait and bradykinesia in patients with Parkinson's disease (PD). In a double-blind placebo-controlled study, we evaluated the effects of 25 Hz rTMS in 18 PD patients. Eight rTMS sessions were performed over a 4-week period. Four cortical targets (left and right motor and dorsolateral prefrontal cortex) were stimulated in each session, with 300 pulses each, 100% of motor threshold intensity. Left motor cortex (MC) excitability was assessed using motor evoked potentials (MEPs) from the abductor pollicis brevis. During the 4 weeks, times for executing walking and complex hand movements tests gradually decreased. The therapeutic rTMS effect lasted for at least 1 month after treatment ended. Right-hand bradykinesia improvement correlated with increased MEP amplitude evoked by left MC rTMS after individual sessions, but improvement overall did not correlate with MC excitability. rTMS sessions appear to have a cumulative benefit for improving gait, as well as reducing upper limb bradykinesia in PD patients. Although short-term benefit may be due to MC excitability enhancement, the mechanism of cumulative benefit must have another explanation.
DOI: 10.1002/mds.20713
PubMed: 16211618
Links to Exploration step
pubmed:16211618Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Placebo-controlled study of rTMS for the treatment of Parkinson's disease.</title><author><name sortKey="Lomarev, Mikhail P" sort="Lomarev, Mikhail P" uniqKey="Lomarev M" first="Mikhail P" last="Lomarev">Mikhail P. Lomarev</name><affiliation><nlm:affiliation>Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892-1428, USA. lomarev@ninds.nih.gov</nlm:affiliation></affiliation></author><author><name sortKey="Kanchana, Sulada" sort="Kanchana, Sulada" uniqKey="Kanchana S" first="Sulada" last="Kanchana">Sulada Kanchana</name></author><author><name sortKey="Bara Jimenez, William" sort="Bara Jimenez, William" uniqKey="Bara Jimenez W" first="William" last="Bara-Jimenez">William Bara-Jimenez</name></author><author><name sortKey="Iyer, Meena" sort="Iyer, Meena" uniqKey="Iyer M" first="Meena" last="Iyer">Meena Iyer</name></author><author><name sortKey="Wassermann, Eric M" sort="Wassermann, Eric M" uniqKey="Wassermann E" first="Eric M" last="Wassermann">Eric M. Wassermann</name></author><author><name sortKey="Hallett, Mark" sort="Hallett, Mark" uniqKey="Hallett M" first="Mark" last="Hallett">Mark Hallett</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="doi">10.1002/mds.20713</idno><idno type="RBID">pubmed:16211618</idno><idno type="pmid">16211618</idno><idno type="wicri:Area/PubMed/Corpus">002E37</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Placebo-controlled study of rTMS for the treatment of Parkinson's disease.</title><author><name sortKey="Lomarev, Mikhail P" sort="Lomarev, Mikhail P" uniqKey="Lomarev M" first="Mikhail P" last="Lomarev">Mikhail P. Lomarev</name><affiliation><nlm:affiliation>Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892-1428, USA. lomarev@ninds.nih.gov</nlm:affiliation></affiliation></author><author><name sortKey="Kanchana, Sulada" sort="Kanchana, Sulada" uniqKey="Kanchana S" first="Sulada" last="Kanchana">Sulada Kanchana</name></author><author><name sortKey="Bara Jimenez, William" sort="Bara Jimenez, William" uniqKey="Bara Jimenez W" first="William" last="Bara-Jimenez">William Bara-Jimenez</name></author><author><name sortKey="Iyer, Meena" sort="Iyer, Meena" uniqKey="Iyer M" first="Meena" last="Iyer">Meena Iyer</name></author><author><name sortKey="Wassermann, Eric M" sort="Wassermann, Eric M" uniqKey="Wassermann E" first="Eric M" last="Wassermann">Eric M. Wassermann</name></author><author><name sortKey="Hallett, Mark" sort="Hallett, Mark" uniqKey="Hallett M" first="Mark" last="Hallett">Mark Hallett</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Evoked Potentials, Motor (physiology)</term><term>Female</term><term>Hand (physiopathology)</term><term>Humans</term><term>Hypokinesia (physiopathology)</term><term>Hypokinesia (therapy)</term><term>Male</term><term>Middle Aged</term><term>Motor Cortex (physiopathology)</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson Disease (therapy)</term><term>Prefrontal Cortex (physiopathology)</term><term>Severity of Illness Index</term><term>Transcranial Magnetic Stimulation (instrumentation)</term><term>Walking</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="instrumentation" xml:lang="en"><term>Transcranial Magnetic Stimulation</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Evoked Potentials, Motor</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Hand</term><term>Hypokinesia</term><term>Motor Cortex</term><term>Parkinson Disease</term><term>Prefrontal Cortex</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Hypokinesia</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Severity of Illness Index</term><term>Walking</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study is to assess the safety and efficacy of repetitive transcranial magnetic stimulation (rTMS) for gait and bradykinesia in patients with Parkinson's disease (PD). In a double-blind placebo-controlled study, we evaluated the effects of 25 Hz rTMS in 18 PD patients. Eight rTMS sessions were performed over a 4-week period. Four cortical targets (left and right motor and dorsolateral prefrontal cortex) were stimulated in each session, with 300 pulses each, 100% of motor threshold intensity. Left motor cortex (MC) excitability was assessed using motor evoked potentials (MEPs) from the abductor pollicis brevis. During the 4 weeks, times for executing walking and complex hand movements tests gradually decreased. The therapeutic rTMS effect lasted for at least 1 month after treatment ended. Right-hand bradykinesia improvement correlated with increased MEP amplitude evoked by left MC rTMS after individual sessions, but improvement overall did not correlate with MC excitability. rTMS sessions appear to have a cumulative benefit for improving gait, as well as reducing upper limb bradykinesia in PD patients. Although short-term benefit may be due to MC excitability enhancement, the mechanism of cumulative benefit must have another explanation.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16211618</PMID><DateCreated><Year>2006</Year><Month>03</Month><Day>15</Day></DateCreated><DateCompleted><Year>2006</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Placebo-controlled study of rTMS for the treatment of Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>325-31</MedlinePgn></Pagination><Abstract><AbstractText>The objective of this study is to assess the safety and efficacy of repetitive transcranial magnetic stimulation (rTMS) for gait and bradykinesia in patients with Parkinson's disease (PD). In a double-blind placebo-controlled study, we evaluated the effects of 25 Hz rTMS in 18 PD patients. Eight rTMS sessions were performed over a 4-week period. Four cortical targets (left and right motor and dorsolateral prefrontal cortex) were stimulated in each session, with 300 pulses each, 100% of motor threshold intensity. Left motor cortex (MC) excitability was assessed using motor evoked potentials (MEPs) from the abductor pollicis brevis. During the 4 weeks, times for executing walking and complex hand movements tests gradually decreased. The therapeutic rTMS effect lasted for at least 1 month after treatment ended. Right-hand bradykinesia improvement correlated with increased MEP amplitude evoked by left MC rTMS after individual sessions, but improvement overall did not correlate with MC excitability. rTMS sessions appear to have a cumulative benefit for improving gait, as well as reducing upper limb bradykinesia in PD patients. Although short-term benefit may be due to MC excitability enhancement, the mechanism of cumulative benefit must have another explanation.</AbstractText><CopyrightInformation>(c) 2005 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lomarev</LastName><ForeName>Mikhail P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892-1428, USA. lomarev@ninds.nih.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanchana</LastName><ForeName>Sulada</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bara-Jimenez</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Iyer</LastName><ForeName>Meena</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wassermann</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Hallett</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019054">Evoked Potentials, Motor</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006225">Hand</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018476">Hypokinesia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009044">Motor Cortex</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017397">Prefrontal Cortex</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D050781">Transcranial Magnetic Stimulation</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000295">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016138">Walking</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.20713</ArticleId><ArticleId IdType="pubmed">16211618</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E37 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002E37 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:16211618
|texte= Placebo-controlled study of rTMS for the treatment of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:16211618" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |